Needham & Company Reiterates Buy Following Imperva's (IMPV) 4Q Beat and Raise
Needham & Company maintained a Buy rating on Imperva (NYSE: IMPV), and cut the price target to $56.00 (from $88.00) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
